share_log

EF Hutton Initiates Coverage On ImmunityBio With Buy Rating, Announces Price Target of $30

EF Hutton Initiates Coverage On ImmunityBio With Buy Rating, Announces Price Target of $30

EF Hutton啓動對ImmunityBio的覆蓋,給予買入評級,公佈目標價格爲30美元
Benzinga ·  2024/10/23 04:11  · 評級/大行評級

EF Hutton analyst Jason Kolbert initiates coverage on ImmunityBio (NASDAQ:IBRX) with a Buy rating and announces Price Target of $30.

EF Hutton的分析師Jason Kolbert開始對ImmunityBio(納斯達克:IBRX)進行覆蓋,給予買入評級,並公佈目標股價爲30美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論